The Holy Grail: Illumina Buys Cancer Blood-Test Startup for $7 Billion

Biotech has become a huge area of venture investment, especially in the past decade. As medical, genetic, and biological advancements move forward, the more money these genetic sequencing companies will rake in. Grail is a spinoff company of Illumina. Illumina originally invested $100 million dollars